Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Income (2018 - 2025)

Historic Operating Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$16.5 million.

  • Arcturus Therapeutics Holdings' Operating Income fell 5378.6% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.3 million, marking a year-over-year increase of 273.01%. This contributed to the annual value of -$95.7 million for FY2024, which is 2233.11% down from last year.
  • Arcturus Therapeutics Holdings' Operating Income amounted to -$16.5 million in Q3 2025, which was down 5378.6% from -$11.6 million recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Operating Income peaked at $121.5 million during Q4 2022, and registered a low of -$57.7 million during Q1 2021.
  • Its 5-year average for Operating Income is -$21.6 million, with a median of -$22.1 million in 2022.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Operating Income tumbled by 50944.83% in 2021, and later skyrocketed by 42262.45% in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Operating Income stood at -$37.6 million in 2021, then surged by 422.62% to $121.5 million in 2022, then tumbled by 115.04% to -$18.3 million in 2023, then tumbled by 82.76% to -$33.4 million in 2024, then surged by 50.55% to -$16.5 million in 2025.
  • Its last three reported values are -$16.5 million in Q3 2025, -$11.6 million for Q2 2025, and -$16.8 million during Q1 2025.